비호지킨 림프종의 질환 부담

Disease Burden of Non-Hodgkin Lymphoma

Studies on the burden of disease for the patients with non-Hodgkin’s lymphoma (NHL) which accounts for about 90 percent of lymphoma are still insufficient. Thus, this study was conducted to assess mortality and economic burden of NHL overall and subtypes. This analysis based on a sample cohort database from the National Health Insurance Sharing Service. ICD-10 codes were used to select NHL patients (C82-86, C96) and to classify subtype of NHL. A retrospective cohort design was applied and patients and their matching controls were compared on survival and medical expenditure using Cox hazard proportion model and generalized linear regression. The 5-year survival rates were 66.2% in NHL total patients (n=521) and 61.7% in diffuse large B-cell lymphoma and male and aged ≥80 showed higher risk for survival. The 5-year cumulative medical expenditure after first diagnosis of NHL was 37.1 million won, and about 44% of the expenses were spent during the first year. The 5-year costs were 4.09 times higher than those of controls, and comorbidity index, older age, and death increased the medical expenditure. In conclusion, NHL caused lower survival and higher medical costs compared to the non-cancer controls, and this study confirmed that subtype of NHL, gender, age, comorbidity and death had a significant impact on the burden of the disease.